Category Archives: Latest News
Genetic Signatures’ are proud to announce we will be exhibiting at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 21-24 April 2018 in Madrid, Spain.
It is a pleasure to announce that Medical Scientist, Elaine McGrath from the University Hospital, Galway, has been selected to present a scientific poster titled “Evaluation of the EasyScreenTM CPO 3baseTM real-time PCR assay for detection of Carbapenemase genes directly from rectal swabs.”
The poster will highlight Genetic Signatures’ proprietary 3base™ technology and upcoming EasyScreenTM ESBL/CPO detection kit, which simultaneously identifies 16 of the most common Anti-microbial resistant pathogen strains.
Abstract No: 6682
Session type: Paper Poster Session #P2322
Session name: Detection of carbapenem resistance
Session date: 24/04/2018
Session time: 12:30h – 13:30h CEST
Genetic Signatures will also exhibit the EasyScreen™ products for the detection of infectious diseases, including kits for diagnosing Enteric bacterial, viral and protozoan pathogens, Respiratory pathogens, Sexual Health pathogens, Tropical disease pathogens, and Meningitis.
Visit Genetic Signatures at Booth #83 at ECCMID 2018 for more information. Click here to visit ECCMID 2018
About ESBL and CPO: ESBLs are enzymes that mediate resistance to extended-spectrum (third generation) cephalosporins and monobactams but do not affect cephamycins or carbapenems. The presence of an ESBL-producing organism in a clinical infection can result in treatment failure if one of the above classes of drugs is used. ESBLs can be difficult to detect because they have different levels of activity against various cephalosporins. Thus, the choice of which antimicrobial agents to test is critical. 1
CPO or CRE, which stands for carbapenemase producing organisms or carbapenem-resistant Enterobacteriaceae organisms, are a family of germs that are difficult to treat because they have high levels of resistance to antibiotics. Klebsiella species and Escherichia coli (E. coli) are examples of Enterobacteriaceae, a normal part of the human gut bacteria, that can become carbapenem-resistant. Types of CRE are sometimes known as KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi Metallo-beta-lactamase). KPC and NDM are enzymes that break down carbapenems and make them ineffective. Both of these enzymes, as well as the enzyme VIM (Verona Integron-Mediated Metallo-β-lactamase) have also been reported in Pseudomonas.
Healthy people usually do not get CRE infections – they usually happen to patients in hospitals, nursing homes, and other healthcare settings. Patients whose care requires devices like ventilators (breathing machines), urinary (bladder) catheters, or intravenous (vein) catheters, and patients who are taking long courses of certain antibiotics are most at risk for CRE infections.
Some CRE bacteria have become resistant to most available antibiotics. Infections with these germs are very difficult to treat, and can be deadly-one report cites they can contribute to death in up to 50% of patients who become infected.2
About the EasyScreen™ Antibiotic Resistance Detection Kit: The EasyScreen™ Antibiotic Resistance Detection Kit detects the most common resistant markers. ESBL and CPO targets that are detected are β –Lactamases TEM, SHV, CTX-M, CMY, DHA, OXA-48 like, OXA- 23 like, OXA-51 like, GES, MCR-1,IMI,SME, , New Delhi Metallo- β –Lactamases (NDM), Klebsiella pneumoniae carbapenemase (KPC), Metallo- β –Lactamases VIM, Metallo- β –Lactamases IMP
About ECCMID: The 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is one of the largest European Infectious diseases meetings. The congress provides a forum for the world’s leading experts who come together to discuss the latest developments in diseases, infection control, and clinical microbiology.
Genetic Signatures’ Chief Scientific Officer, Dr. Doug Millar will be presenting at Medical Microbiology Meeting (MMM) 2018 in Sydney, Australia on April 12th.
MMM provides a forum for research scientists, laboratory staff and clinicians to share the latest issues and developments in the field of molecular microbiology. It has become the principal forum for sharing new molecular diagnostics concepts in Australia. This two-day meeting uses an informal workshop style with encouragement for comments and questions from the floor.
- Thursday 12th April 2018 16:25-16: 35 pm EST
Presentation title: Irish evaluation of the EasyScreen™ ESBL/CPO Detection Kit Using Primary Patient Swabs.
Come along and chat to our team at Genetic Signatures at MMM 2018 Sydney, Australia for more information on our EasyScreenTM Detection Kits and learn more about 3baseTM technology.
Click here to visit the MMM 2018 Sydney website
For a second year, Genetic Signatures Ltd are proudly exhibiting at the 25th International Molecular Medicine TRI-Conference (MMTC) in San Francisco, CA on 12th-14thFebruary 2018.
Our US operations team will be exhibiting our growing number of EasyScreenTM viral and infectious disease reagents. Formulated on our proprietary 3base™ technology, the EasyScreenTM reagents fosters more efficient detection of infectious microorganisms, within a streamlined workflow solution. The EasyScreenTM reagents includes targets for diagnosing bacterial, viral and protozoan causes of gastroenteritis; respiratory infections, sexually transmitted infections, and antibiotic resistance.
Visit Genetic Signatures at Booth 221 MMTC 2018 for more information
Don’t forget to follow us on Twitter @GeneticSig for updates throughout the conference.
About MMTC 2018: MMTC also known as Tri-Con, is an annual precision medicine event attracting over 3,700 drug discovery and development professionals worldwide. Spanning five days, the 2018 meeting includes over 500 fellow industry and academic colleagues discussing themes of cancer research, big data, molecular diagnostics, precision medicine, rare diseases, data science, human microbiome, point-of-care diagnostics, infectious diseases, and so much more.
Genetic Signatures are pleased to inform our customers and distributors that we have recently relocated our Sydney Office.
Our relocation enables advancement of our growth expectations for the future and further support our customers through our commitment of high quality products and services.
Our contact number will remain unchanged.
Our new address:
7 Eliza Street, Newtown NSW 2042 Australia.
Genetic Signatures Limited (ASX: GSS) held its 2017 Annual General Meeting on Tuesday 28 November 2017 at 11.00am (AEST).
Genetic Signatures are exhibiting at the Association for Molecular Pathology (AMP) Annual meeting 2017 in Salt Lake City, Utah 16-18 November.
The AMP Annual Meeting is:
- The premier educational event for molecular pathology professionals from around the world.
- The only educational event developed and presented by internationally renowned molecular diagnostic professionals.
- The dedicated forum for first-time presentation of rigorously peer-reviewed abstracts, destined for publication in The Journal of Molecular Diagnostics.
- The source for practical applications of clinically proven molecular diagnostics – ultimately improving patient care.
You are invited to visit Genetic Signatures at Booth no. 1005 at AMP 2017 for more information.
Click here to visit the AMP 2017
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP’s 2,300+ members practice in the various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions, and oncology. Our members include pathologists, doctoral scientist laboratory directors, basic and translational scientists, technologists, and trainees from academic and community medical centers, government, and industry. Through the efforts of its Board of Directors, Committees, Working Groups, and Members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing.